Should FDA Priority Review of Dyne’s DMD Drug Candidate Reshape Risk Expectations for Dyne Therapeutics (DYN) Investors?
Dyne Therapeutics, Inc. recently reported that the U.S. FDA accepted for review its biologics license application for zeleciment rostudirsen (z-rostudirsen, […]









